OM:BIOA BBiotechs
BioArctic (OM:BIOA B): Valuation Insights Following New Subcutaneous Leqembi Filing in Japan
BioArctic (OM:BIOA B) and its partner Eisai have filed a new drug application in Japan for a subcutaneous version of Leqembi, their Alzheimer’s treatment. This approach could allow patients to receive injections at home, based on positive Phase 3 data.
See our latest analysis for BioArctic.
BioArctic’s momentum has been picking up, with this year’s breakthroughs helping to drive a strong 45% year-to-date share price return and a 58% total shareholder return over the past year. Recent...